Nahibu

Established in 2013, NuBiyota is a pioneer in next-generation microbiome drug development. NuBiyota holds an exclusive license to the groundbreaking research developed at the University of Guelph, and led by co-founder, Dr. NuBiyota employs a world-class group of scientists and is led by a seasoned management team with extensive management and business development experience in the healthcare industry. NuBiyota has entered a strategic collaboration with the Takeda Pharmaceutical Company for the development of NuBiyota’s Microbial Ecosystem Therapeutic products for gastroenterology (GI) indications. NuBiyota carries out its research activities in its state-of-the-art labs in Guelph, ON, Canada and has established a GMP manufacturing site in Pearl River, NY, USA. NuBiyota is a microbiome therapeutics company focused on the development of novel microbiota-based drugs to restore crucial gut equilibrium. NuBiyota is developing a new class of microbiome therapeutics, with multi-strain microbiota candidates for effective microbiota diversity restoration to suppress flares or promote remission in numerous indications.

Holobiome was founded by research scientists from Northeastern University with the singular mission of unlocking that potential to improve global health. Driven by a passion for improving health and dedicated to scientific rigor, we’re translating the emerging science of the human microbiome into the next generation of probiotics and targeted solutions for whole-body health.

The Biomesight microbiome test provides a snapshot of the gut microbiome utilizing 16S rRNA sequencing technology. Using this method we are able to provide relative abundances of all bacterial organisms in your sample rather than targeting just a small subset of bacteria. We provide an interpretation using Dr Jason Hawrelak's (Probiotic Advisor) recommended ranges for a subset of key bacteria (Probiotics, Commensals and Pathobionts) along with our scoring system, diversity calculation and personalized recommendations for food, supplements and lifestyle adjustments based on up-to-date research findings. Biomesight is the only gut microbiome analysis platform with support for FASTQ uploads from multiple labs. Provide personalised recommendations based on your unique microbiome and health profile. All data feeds back into our recommendation algorithms leading to further insights. Rose is a technologist & serial entrepreneur with over 20 years experience across software, cloud & machine learning technologies.

G-NiiB GenieBiome holds a comprehensive and unique databank for unlimited microbiome discoveries. Our expanding disease-specific microbial datasets compared with a comprehensive control microbial dataset provide a rich source for novel therapeutic candidates. If you are interested to join us in world-leading gut microbiome research and development, we'll help you find the right investment or partnership within our innovative platforms.

Neobiomics is a budding company rooted in academia and we collaborate with experts from the industry. We are dedicated to bringing innovative ideas to life. Since then, Neobiomics has expanded and collaborated with many similar-minded committed experts in science, technology, design, and business. Today, we are a strong team-building self-propelling, and sustainable startup company.”. Our products are intended to be available long-term. Neobiomics has its fiscal base in Sweden, as an incorporated company (Swe. Neobiomics offers the best dietary supplement solutions today. With collaborations all across Europe, we provide superior quality multi-strain food supplement.

At Nexbiome Therapeutics, we define the microbiome as an ecosystem of microorganisms, the composition of which predisposes to health or to illness. Consequently, we are convinced that the microbiome represents the reservoir of therapeutic solutions for the future of human health. Our mission is to identify the best research projects and turn them into biotech companies that will bring innovative health solutions to the market. Nexbiome Therapeutics was built on this heritage, made of innovation and audacity, and validated R&D assets. Since 2020, Nexbiome Therapeutics has been acting as a fully independent company that promotes its research pipeline. Assessment of projects in relation to patient’s need and the scientific state-of-the-art. Complete control over pharmaceutical development, from discovery to product registration. In 1975, Lcr35 became the active ingredient of the first microbiome-derived medicinal product in the world: Antibiophilus®.